Satellos Bioscience Inc. (TSX:MSCL)

Canada flag Canada · Delayed Price · Currency is CAD
10.03
+0.98 (10.83%)
Apr 13, 2026, 3:59 PM EST
Market Cap188.52M +42.1%
Revenue (ttm)n/a
Net Income-34.10M
EPS-2.34
Shares Out20.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,876
Average Volume26,141
Open9.21
Previous Close9.05
Day's Range9.00 - 10.10
52-Week Range6.24 - 18.98
Beta1.08
RSI48.15
Earnings DateMay 13, 2026

About Satellos Bioscience

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British C... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 21
Stock Exchange Toronto Stock Exchange
Ticker Symbol MSCL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements